Table 6 Changes in intrinsic subtype after neoadjuvant chemotherapy. Differences between pre- and post-chemotherapy assessments were not statistically significant.
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
Subtype post-chemotherapy | Total | |||||
|---|---|---|---|---|---|---|
HER2+ | Luminal A | Luminal B HER2− | Luminal B HER2+ | Triple negative | ||
Subtype pre-chemotherapy | ||||||
HER2+ | 18 | 1 | 1 | 1 | 0 | 21 |
Luminal A | 0 | 36 | 12 | 0 | 0 | 48 |
Luminal B HER2− | 0 | 4 | 24 | 1 | 1 | 30 |
Luminal B HER2+ | 0 | 2 | 3 | 20 | 0 | 25 |
Triple Negative | 0 | 2 | 0 | 0 | 32 | 34 |
Total | 18 | 45 | 40 | 22 | 33 | 158 |
